Laura Castro-Labrador

Laura Castro-Labrador

Auto-generated profile, based on publicly available information

Laura Castro-Labrador

Topazium Artificial Intelligence, Madrid, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2020 in Circulation
Verified
Journal Article
Closed access
PDF file
ARAdrián Ruiz-Villalba
Adrián Ruiz-Villalba
JRJuan P. Romero
Juan P. Romero
SHSilvia C. Hernández
Silvia C. Hernández
AVAmaia Vilas-Zornoza
Amaia Vilas-Zornoza
NFNikolaus Fortelny
Nikolaus Fortelny
FPFelipe Prosper
Felipe Prosper
Background: Cardiac fibroblasts (CFs) have a central role in the ventricular remodeling process associated with different types of fibrosis. Recent studies have shown that fibroblasts do not respond homogeneously to heart injury. Because of the limited set of bona fide fibroblast markers, a proper characterization of fibroblast population heterogeneity in response to cardiac damage is lacking. The purpose of this study was to define CF heterogeneity during ventricular remodeling and the underlying mechanisms that regulate CF function. Methods: Collagen1α1–GFP (green fluorescent protein)–positive CFs were characterized after myocardial infarction (MI) by single-cell and bulk RNA sequencing, assay for transposase-accessible chromatin sequencing, and functional assays. Swine and patient samples were studied using bulk RNA sequencing. Results: We identified and characterized a unique CF subpopulation that emerges after MI in mice. These activated fibroblasts exhibit a clear profibrotic signature, express high levels of Cthrc1 (collagen triple helix repeat containing 1), and localize into the scar. Noncanonical transforming growth factor–β signaling and different transcription factors including SOX9 are important regulators mediating their response to cardiac injury. Absence of CTHRC1 results in pronounced lethality attributable to ventricular rupture. A population of CFs with a similar transcriptome was identified in a swine model of MI and in heart tissue from patients with MI and dilated cardiomyopathy. Conclusions: We report CF heterogeneity and their dynamics during the course of MI and redefine the CFs that respond to cardiac injury and participate in myocardial remodeling. Our study identifies CTHRC1 as a novel regulator of the healing scar process and a target for future translational studies.

17 February 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
ACArantxa Carrasco-Leon
Arantxa Carrasco-Leon
TETeresa Ezponda
Teresa Ezponda
CMCem Meydan
Cem Meydan
LVLuis V. Valcárcel
Luis V. Valcárcel
RORaquel Ordoñez
Raquel Ordoñez
XAXabier Agirre
Xabier Agirre
Multiple myeloma (MM) is an incurable disease, whose clinical heterogeneity makes its management challenging, highlighting the need for biological features to guide improved therapies. Deregulation of specific long non-coding RNAs (lncRNAs) has been shown in MM, nevertheless, the complete lncRNA transcriptome has not yet been elucidated. In this work, we identified 40,511 novel lncRNAs in MM samples. lncRNAs accounted for 82% of the MM transcriptome and were more heterogeneously expressed than coding genes. A total of 10,351 overexpressed and 9,535 downregulated lncRNAs were identified in MM patients when compared with normal bone-marrow plasma cells. Transcriptional dynamics study of lncRNAs in the context of normal B-cell maturation revealed 989 lncRNAs with exclusive expression in MM, among which 89 showed de novo epigenomic activation. Knockdown studies on one of these lncRNAs, SMILO (specific myeloma intergenic long non-coding RNA), resulted in reduced proliferation and induction of apoptosis of MM cells, and activation of the interferon pathway. We also showed that the expression of lncRNAs, together with clinical and genetic risk alterations, stratified MM patients into several progression-free survival and overall survival groups. In summary, our global analysis of the lncRNAs transcriptome reveals the presence of specific lncRNAs associated with the biological and clinical behavior of the disease.

9 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
NBNerea Berastegui
Nerea Berastegui
MAMarina Ainciburu
Marina Ainciburu
JRJuan P. Romero
Juan P. Romero
PGPaula Garcia-Olloqui
Paula Garcia-Olloqui
AAAna Alfonso-Pierola
Ana Alfonso-Pierola
FPFelipe Prosper
Felipe Prosper
Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) malignancies characterized by ineffective hematopoiesis, with increased incidence in older individuals. Here we analyze the transcriptome of human HSCs purified from young and older healthy adults, as well as MDS patients, identifying transcriptional alterations following different patterns of expression. While aging-associated lesions seem to predispose HSCs to myeloid transformation, disease-specific alterations may trigger MDS development. Among MDS-specific lesions, we detect the upregulation of the transcription factor DNA Damage Inducible Transcript 3 (DDIT3). Overexpression of DDIT3 in human healthy HSCs induces an MDS-like transcriptional state, and dyserythropoiesis, an effect associated with a failure in the activation of transcriptional programs required for normal erythroid differentiation. Moreover, DDIT3 knockdown in CD34+ cells from MDS patients with anemia is able to restore erythropoiesis. These results identify DDIT3 as a driver of dyserythropoiesis, and a potential therapeutic target to restore the inefficient erythroid differentiation characterizing MDS patients.

17 January 2022 in Plant, Cell & Environment
Verified
Journal Article
Closed access
PDF file
LPLaura Poza‐Viejo
Laura Poza‐Viejo
MMMiriam Payá Milans
Miriam Payá Milans
PMPatxi San Martin-Uriz
Patxi San Martin-Uriz
LCLaura Castro‐Labrador
Laura Castro‐Labrador
DLDavid Lara‐Astiaso
David Lara‐Astiaso
PCPedro Crevillén
Pedro Crevillén

26 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
LLL Castro Labrador
L Castro Labrador
RZR Zamora
R Zamora
SSS Szyldergemajn
S Szyldergemajn
PCP Gómez del Campo
P Gómez del Campo
JCJ Castillo-Izquierdo
J Castillo-Izquierdo
Carlos María GalmariniCarlos María Galmarini
Carlos María Galmarini
Purpose: Castration-resistant prostate cancer (CRPC) is characterized by marked clinical heterogeneity and poor long-term survival, underscoring the need for tools that can rapidly and reliably individualize patient risk. While several prognostic models exist, their complexity has limited routine clinical use. Here, we developed and validated PROGRESS (PROstate cancer Global Risk Evaluation and Stratification Score), a simplified prognostic score, derived through machine learning-guided feature selection, to enhance risk stratification and support individualized, risk-informed clinical decision-making. Methods: PROGRESS was developed using baseline data from 2,035 metastatic CRPC patients enrolled in four different phase III trials. An unsupervised machine-learning approach was applied to identify latent patient subgroups with distinct survival outcomes irrespectively of allocated treatment arm, followed by classical multivariable modelling to derive a simple and straight-forward prognostic score based on routinely available objective laboratory variables. External validation was performed in three independent datasets comprising metastatic CRPC patients treated across different therapeutic settings (n=1,239) and non-metastatic CRPC patients managed with standard care (n=660). Overall survival was assessed using Kaplan-Meier and Cox regression analyses. Results: Unsupervised modelling identified two patient risk subpopulations with significantly different overall survival rates (median 27.4 vs 17.7 months; hazard ratio [HR] 2.20, 95% CI 1.91–2.54; p<.00001). Feature contribution analysis yielded three independent predictors -PSA, ALP, and AST-used to build PROGRESS. In the training cohort, PROGRESS demonstrated strong discrimination (AUC 0.89). Using a prespecified cut-off, patients classified as increased risk had significantly shorter survival than low-risk patients (median 18.3 vs 25.6 months; HR 1.72, 95% CI 1.50–1.97; p<.0001). PROGRESS prognostic performance was consistent across all validation cohorts, including metastatic and non-metastatic disease, with HRs ranging from 1.74 to 3.46 (all p<.0001). Conclusions: By integrating machine-learning-based pattern discovery with classical statistical modelling, PROGRESS provides a simple, objective, and clinically accessible approach for individual risk stratification in CRPC. Its reliance on three inexpensive, routinely measured laboratory parameters would facilitate practical implementation in clinical settings, enhancing visibility of underlying disease aggressiveness for individual clinical decision-making. PROGRESS could represent a pragmatic first step toward improving patient selection for clinical trials while identifying regulatory meaningful endpoints achievable in a sizeable patient population; further validation in prospective clinical studies and real-world datasets would allow to confirm its clinical utility and generalizability. PROGRESS can be freely accessed for research use only at the following link: https://dev.ai.topazium.com .

1 October 2026 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
LCLaura Castro-Labrador
Laura Castro-Labrador
RZRafael Zamora
Rafael Zamora
SSSergio Szyldergemajn
Sergio Szyldergemajn
PCPablo Gómez del Campo
Pablo Gómez del Campo
JIJosé Del Castillo Izquierdo
José Del Castillo Izquierdo
Carlos María GalmariniCarlos María Galmarini
Carlos María Galmarini
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) shows marked clinical heterogeneity and poor long-term survival, highlighting the need for simple and reliable risk stratification tools beyond the limited usability of existing complex prognostic models. In this study, we developed and validated PROGRESS (Prostate Cancer Global Risk Evaluation and Stratification Score), a simplified prognostic score derived through machine learning‑guided feature selection distilled into a simple laboratory-based tool. Methods: Baseline data from 2,035 patients with mCRPC (training set) were embedded into synthetic representations, reduced with UMAP, and clustered with DBSCAN to discover outcome-related subpopulations. Feature contribution analysis informed a multivariable model that yielded three independent predictors (prostate specific antigen [PSA], alkaline phosphatase [ALP], and AST) composing PROGRESS. External validation used two independent data sets (n = 1,239) across different therapeutic settings. Overall survival (OS) was analyzed with Kaplan-Meier and Cox regression; discrimination was assessed by ROC-AUC, AUC(t), and Harrel C-index. Results: Unsupervised modeling identified two patient risk subpopulations with significantly different OS rates (median 27.4 v 17.7 months; hazard ratio [HR], 2.20 [95% CI, 1.91 to 2.54]; P < .00001). The three retained predictors (PSA, ALP, and AST) were combined into a composite score (PROGRESS) that showed strong discrimination in the training cohort (ROC-AUC 0.89; AUC(t) 0.60; Harrel C-index 0.69). Using a prespecified cutoff, patients classified by PROGRESS as increased risk had significantly shorter survival than low-risk patients (median 18.3 v 25.6 months; HR, 1.72 [95% CI, 1.50 to 1.97]; P < .0001). PROGRESS prognostic performance was consistent across all validation cohorts (all P < .0001). Conclusion: By combining ML-based pattern discovery with classical modeling, PROGRESS provides a simple, objective, and readily implementable prognostic tool using three inexpensive routine laboratory measures. Its consistent performance across independent data sets supports clinical utility for individual risk stratification, trial enrichment, and early decision making. Prospective real-world validation is warranted.